Proteomic Analysis Reveals that Proteasome Subunit Beta 6 Is Involved in Hypoxia-Induced Pulmonary Vascular Remodeling in Rats

Jian Wang1,2*, Lei Xu1,2*, Xin Yun1,2, Kai Yang1,2, Dongjiang Liao1, Lichun Tian1, Haiyang Jiang2, Wenju Lu1,3*

1 Guangzhou Institute of Respiratory Diseases, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China, 2 Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, 3 Department of Laboratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China

Abstract

**Background:** Chronic hypoxia (CH) is known to be one of the major causes of pulmonary hypertension (PH), which is characterized by sustained elevation of pulmonary vascular resistance resulting from vascular remodeling. In this study, we investigated whether the ubiquitin proteasome system (UPS) was involved in the mechanism of hypoxia-induced pulmonary vascular remodeling. We isolated the distal pulmonary artery (PA) from a previously defined chronic hypoxic pulmonary hypertension (CHPH) rat model, performed proteomic analyses in search of differentially expressed proteins belonging to the UPS, and subsequently identified their roles in arterial remodeling.

**Results:** Twenty-two proteins were differently expressed between the CH and normoxic group. Among them, the expression of proteasome subunit beta (PSMB) 1 and PSMB6 increased after CH exposure. Given that PSMB1 is a well-known structural subunit and PSMB6 is a functional subunit, we sought to assess whether PSMB6 could be related to the multiple functional changes during the CHPH process. We confirmed the proteomic results by real-time PCR and Western blot. With the increase in quantity of the active subunit, proteasome activity in both cultured pulmonary artery smooth muscle cells (PASMCs) and isolated PA from the hypoxic group increased. An MTT assay revealed that the proteasome inhibitor MG132 was able to attenuate the hypoxia-induced proliferation of PASMC in a dose-dependent manner. Knockdown of PSMB6 using siRNA also prevented hypoxia-induced proliferation.

**Conclusion:** The present study revealed the association between increased PSMB6 and CHPH. CH up-regulated proteasome activity and the proliferation of PASMCs, which may have been related to increased PSMB6 expression and the subsequently enhanced functional catalytic sites of the proteasome. These results suggested an essential role of the proteasome during CHPH development, a novel finding requiring further study.

Citation: Wang J, Xu L, Yun X, Yang K, Liao D, et al. (2013) Proteomic Analysis Reveals that Proteasome Subunit Beta 6 Is Involved in Hypoxia-Induced Pulmonary Vascular Remodeling in Rats. PLoS ONE 8(7): e67942. doi:10.1371/journal.pone.0067942

Editor: Joseph Najbauer, University of Pécs Medical School, Hungary

Received March 4, 2013; Accepted May 23, 2013; Published July 3, 2013

Copyright: © 2013 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Institutes of Health (NIH) research grants (R01HL093020), National Natural Science Foundation of China (81070043, 81071917, 81173112, 81170052, 81220108001), Chinese Central Government Key Research Projects of the 973 grants (2009CB522107), Changjiang Scholars and Innovative Research Team in University grant (IRT0961), Guangdong Department of Science and Technology of China (2009B050700041, 2010B03160030), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2008) China, Guangdong Department of Education research grant (czzd1025), Guangdong Natural Science Foundation team grant (2010), Guangzhou Department of Education Yangcheng Scholarship (10A058S, 12A001S). Lei Xu was supported by the Guangzhou Elite Scholarship Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wlu92@yahoo.com (WL); jwang31@jhmi.edu (JW)

These authors contributed equally to this work.

Introduction

Pulmonary hypertension (PH) is characterized by increased pulmonary artery pressure (PAP) and structural changes in the walls of pulmonary arteries (PA) causing pulmonary vascular remodeling. This disorder eventually leads to right ventricular failure and death. In addition to being a primary disorder, PH is also an accompanying complication of a variety of cardiopulmonary diseases, for example chronic obstructive pulmonary disease (COPD), which is highly prevalent and continues to be an increasing cause of morbidity and mortality worldwide [1,2]. For patients with COPD, structural and functional changes in the PA induced by chronic hypoxia (CH) are associated with the development of PH. Despite numerous studies on the morphological and functional changes in PH in response to CH, the underlying cellular and molecular mechanisms remain unclear.

During the past decades, a series of proteins, including hypoxia-inducible factor (HIF) and bone morphogenetic protein receptor type II (BMPRII) have been shown to be significantly altered...
during the PH disease process in comparison with normal condition. These altered proteins are accompanied with changes in expression levels, and some of these changes have already been identified as participating factors in the remodeling of the pulmonary artery. These data suggest a crucial contribution of the changed levels of such proteins to the progression of PH disease. Protein quantity is controlled by both protein synthesis and protein degradation. The ubiquitin proteasome system (UPS), the major intracellular proteolytic system, is complex in both structure and function [3]. Degradation of proteins by the UPS occurs mainly in two steps: targeting of proteins with ubiquitin and successive degradation by the 26S proteasome. Enhanced proteasome activity is associated with proliferative diseases such as cancer [4–7] and cardiovascular disease [8–13]. The essential roles of the UPS during the degradation of cellular proteins, the regulation of the cell cycle, and the modulation of abnormal cellular proliferation make it an attractive target for the therapy of hyperproliferative chronic lung diseases such as lung cancer [14,15] and pulmonary fibrosis [16]. Proliferation of PASMCs is a critical part of the pathogenesis of CPHPH. However, to date, little is known about the role of the UPS during the development of PH. In consideration of the complex composition of the UPS, we sought to select proteins of interest using high throughput and sensitive methods such as proteomic analyses.

Proteomic analyses have been widely used to identify differentially expressed proteins, thus this technique is one of the most effective methods for delineating the relationship between the UPS and vascular remodeling during the CPHPH process. The CPHPH rat model used in this study is a commonly used model for studying pulmonary vascular remodeling [17,18]. Furthermore, since proliferation of PASMCs is widely accepted as one of the main causes of vascular remodeling [19], we also focused on the medial layer of the distal PA, which is composed of PASMCs. Real-time PCR and Western blot analyses were applied to determine expression changes in mRNA and protein levels, respectively. This study expands the knowledge of the mechanisms of development of CPHPH by successfully demonstrating the involvement of a UPS functional subunit, PSMB6, in a CPHPH rat model. Furthermore, this study uncovers the possibility of the potential contribution of the UPS system in the CPHPH process, which to date, lacks sufficient data and requires further studies for better understanding of the disease process.

Materials and Methods

Exposure of Animals to Chronic Hypoxia

All procedures were approved by the Animal Care and Use Committee of Guangzhou Medical University. Twenty SD rats (male, 8 weeks, 0.25±0.03 kg) were provided by the Guangdong Laboratory Animal Centre, Guangzhou, China. These rats were randomized into two groups, the CH group and the control group. Rats in the CH group were placed in a hypoxic chamber for 21 days. As previously described [20], the chamber was continuously flushed with a mixture of room air and N2 to maintain 10±0.5% O2 and CO2<0.5%. The O2 concentration in the chamber was continuously monitored using a PRO-OX unit (RCI Hudson, Anaheim, CA). Animals were exposed to room air for 10 minutes, once a week for cage cleaning and replenishment of food and water. Rats in the normoxia control group were housed in ambient room air next to the hypoxic chambers. The CPHPH model was assessed by measuring the ratio of the right ventricle to left ventricle plus septum weight RV/(LV+SV) and mean pulmonary artery pressure (mPAP).

Preparation of Pulmonary Arteries

At the end of the hypoxic exposure, all rats were anesthetized with sodium pentobarbital (65 mg/kg i.p.). The hearts and lungs were removed en bloc and transferred to a petri dish containing a physiological salt solution (PSS; 130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES, and 10 mM glucose; the pH was adjusted to 7.2 with 5 M NaOH). Distal (4th generation) intrapulmonary arteries were dissected from the lungs, and adipose, adventitia, and connective tissues were carefully removed. The tissues were stored at ~80°C prior to use. The arterial tissue was cut into pieces and placed in a glass homogenizer along with 200 μl of protein lysis buffer (7 M Urea, 2 M Thiourea,4% (w/v) CHAPS, 10 mg/ml DTT,2% Phosphate, and PMSF 20 mg/ml at pH 3–10). The tissue was carefully homogenized, and the solution was placed in a microcentrifuge tube. The samples were subjected to repeated freeze-thaw cycles by switching the protein lysate between liquid nitrogen and a 37°C water bath for three times. Then, the samples were centrifuged at 17000 rpm for 1 h. The supernatant was transferred into a new tube and the protein concentration was measured using the BCA Protein Assay Kit (BioRad, USA).

Culture and Treatment of Rat Distal PASMCs

As previously described [21], the enzymatically isolated PASMCs were seeded in 35 mm culture dishes and cultured in Smooth Muscle Growth Medium-2 (SMGM-2, Clonetics, Walkersville, MD) in a humidified atmosphere of 5% CO2, 95% air at 37°C for 3–4 days. Cells were then growth-arrested in Smooth Muscle Basal Medium (SMBM, Clonetics, Walkersville, MD) containing 0.3% fetal bovine serum for 24 h before being exposed to normoxia or hypoxia (4% O2) in the presence or absence of MG132 for 60 h prior to various assessments. The O2 concentration in the incubator was continuously monitored by an O2 sensor (0–730 flow-through O2 microelectrodes, Microelectrodes Inc, Bedford, NH).

Two-dimensional Electrophoresis (2DE) and Image Analysis

Each sample contained PA isolated from two rats and each group contained 10 rats, i.e., each group had 5 samples. Total amount of 190 μg protein from each sample was loaded onto immobilized pH gradient (IPG) gel strips (GE Healthcare, Biosciences, Uppsala, Sweden) and left overnight at room temperature. Each strip was overlaid with 2–3 ml of mineral oil to prevent evaporation during the rehydration process. The IPG strip was then placed on the tray, and isoelectric focusing was performed at 20°C using the IPG-Phor isoelectric system (BioRad, USA). The initial voltage was set at 250 V and raised stepwise to

Table 1. Verification of the hypoxia-induced PAH model in rats in this study.

| Group     | mPAP (mmHg) | RVSP (mmHg) | RV/(LV+SV) |
|-----------|-------------|-------------|------------|
| Norm      | 116±0.52    | 242±0.08    | 0.26±0.02  |
| Hypo      | 254±0.72*   | 523±1.67*   | 0.55±0.07* |

Norm: normal group n = 10, Hypo: Hypoxia group n = 10; RVSP: Right ventricular systolic pressure, mPAP: mean pulmonary artery pressure, RV/(LV+SV): right ventricle to left ventricle plus septum.

Table 1 illustrates the changes in the pressure indexes after SD rats were placed in a hypoxic atmosphere (10% O2, 21 days). *P<0.01 versus normoxia. doi:10.1371/journal.pone.0067942.t001
4,000 V to remove the salt. The proteins were focused for 8 h at 80,000 V. After equilibration, the IPG strips were analyzed in 2D on a 12% (w/v) SDS polyacrylamide gel performed in a Protean II xi cell vertical electrophoresis tank (Bio-Rad, USA). Subsequently, the 2D gel was silver-stained and scanned. The digital images were analyzed using ImageMaster 2D Platinum 5.0 software (GE, USA) for spot-intensity calibration, spot detection, background abstraction, gel matching, and establishment of the average gel. The differentially expressed spots were defined as having a more than two-fold difference between the control and treated group. All data were statistically analyzed with SPSS 13.0 software and Microsoft Excel 2003.

**Digestion of Proteins and Identification by Matrix-assisted Laser Desorption/ionization Time of Flight Mass Spectrometry**

All five gels from each group were analyzed. The identified protein spots in the gel were excised from the gel and were in-gel digested. Briefly, the gel spots were destained in 30 mmol/L K$_3$Fe(CN)$_6$ and 100 mmol/L Na$_2$S$_2$O$_3$, then dehydrated with 100% acetonitrile and dried in a stream of nitrogen gas. The dried gel pieces were incubated in a digestion solution consisting of 25 mM NH$_4$HCO$_3$ and 12.5 µg/ml trypsin (Promega, USA) for 16–18 h at 37°C. The tryptic peptide mixture was extracted and mixed with matrix a-cyano-4-hydroxycinnamic acid (CHCA) for mass spectrum analysis. Mass spectra results were obtained using an Applied Biosystems Voyager System 4800 matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF) mass spectrometer (ABI, USA) with an accelerating voltage of MS/MS 8000 V. Mass fingerprinting was used for protein identification from tryptic fragment sizes in the NCBI database (http://www.matrixscience.com) and SWISS-PROT database (http://web.expasy.org/docs/swiss-prot_guideline.html) with the MASCOT search engine for information such as protein name, mass score, and peptide match.

**Total RNA Extraction and Real-time PCR**

Total RNA was extracted from the distal PA using the TRIzol reagent (Invitrogen, Carlsbad, CA). RNA quantification and purification were evaluated by measuring absorbance, and A260/A280 ratios in the range of 1.8–2.0 were considered satisfactory for purity standards. Denaturing agarose gel electrophoresis was used to assess the quality of the samples. Synthesis of cDNA was performed by reverse transcription from 1 µg total RNA, and mRNA was reverse transcribed using the iScript cDNA synthesis kit (BioRad). cDNA was quantified with real-time quantitative PCR (qPCR) in an iCycleriQ machine (BioRad) using Quantitect SYBR Green PCR Master Mix (Qiagen). The qPCR reaction mixture of 25 µl contained 200 nM each of the forward and reverse primers and a cDNA template from 6.25 ng of RNA. Primer sequences were as follows (5’-3’): PSMB6 F: (GA-CAAGCTGACCCCTATCCA; R: GCACATGCGAGGGCCTAGG), PSMB1 F: (TCTGACATCGTGACAAA-
Table 2. Up-regulated proteins identified by MS or MS/MS and database searches in the hypoxia group.

| Spot no. | Protein description | Database | Accession no. | Theoretical MW^c/pId | PI Score^d | Intensity Mean ±SEM | Ratio Hypoxia/Normoxia | P Value |
|----------|---------------------|----------|---------------|----------------------|------------|----------------------|------------------------|---------|
| 1        | Transgelin          | SwissProt| P31232[TAGL]  | 22588.3/8.87         | 112        | 0.0248 ± 0.1317      | 0.0069 ± 0.0016        | 3.587   |
| 3        | Phosphotriesterase related protein | NCBInr  | 61889077      | 39120/6.4            | 77         | 0.0079 ± 0.0042      | 0.0024 ± 0.0007        | 3.319   |
| 4        | Hippocalcin like protein 1 | SwissProt| P62749[HPCL1]| 22324/5.32           | 151        | 0.0365 ± 0.0108      | 0.0192 ± 0.0091        | 2.010   |
| 7        | Branched chain specific acyl-CoA dehydrogenase mitochondrial | SwissProt| P70584[ACDSB]| 47793.7/8.27 | 141        | 0.0116 ± 0.0049      | 0.0286 ± 0.0154        | 2.461   |
| 8        | Phosphotriesterase-related protein | SwissProt| Q63530[PTER] | 38906.9/6.06        | 52         | 0.0217 ± 0.0079      | 0.0084 ± 0.0034        | 2.585   |
| 9        | Mannose-1 phosphate guanylyltransferase beta | NCBInr  | 15781724      | 39876.6/6.27         | 84         | 0.0374 ± 0.0108      | 0.0185 ± 0.0045        | 2.023   |
| 12       | Chloride intracellular channel protein 1 | SwissProt| Q6MG61[CUC1]| 26963.8/5.09        | 333        | 0.0605 ± 0.0099      | 0.3000 ± 0.0073        | 2.0137  |
| 13       | Inositol monophosphatase | SwissProt| P97697[IMPA1]| 30491.4/5.17        | 86         | 0.0218 ± 0.0087      | 0.0106 ± 0.0041        | 2.0575  |
| 14       | Proteasome subunit beta type-6 | SwissProt| P28073[PSB6]| 25273.4/4.85        | 77         | 0.0160 ± 0.0017      | 0.0482 ± 0.0059        | 3.011   |
| 15       | Isocitrate dehydrogenase (NAD) subunit alpha, mitochondrial | SwissProt| Q99NA5[IDH3A]| 39588/6.47  | 184        | 0.0587 ± 0.0099      | 0.0262 ± 0.0138        | 2.235   |
| 17       | Von Willebrand factor | SwissProt| Q642A6[VWA1]| 44804.3/6.22        | 108        | 0.0755 ± 0.0264      | 0.0174 ± 0.0070        | 4.330   |
| 18       | Tubulin gamma1 chain | SwissProt| P83888[TBG1]| 51068.7/5.66        | 53         | 0.0558 ± 0.0136      | 0.0272 ± 0.0094        | 2.047   |
| 23       | Endoplasmic reticulum protein ERP29 | SwissProt| P52555[ERP29]| 28556.9/6.23       | 170        | 0.0774 ± 0.0186      | 0.0207 ± 0.0100        | 3.727   |
| 25       | Ribosome binding protein 1 | NCBInr  | 293358103     | 144481.3/9.05       | 141        | 0.0076 ± 0.0019      | 0.0196 ± 0.0066        | 2.5510  |
| 26       | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | SwissProt| Q811A3[PLOD]| 84888.5/6.26       | 116        | 0.0085 ± 0.0008      | 0.6784 ± 0.0525        | 7.9994  |
| 27       | Dihydropyrimidinase related protein 2 | SwissProt| P47942[DPYL2]| 62238.6/5.95       | 137        | 0.0027 ± 0.0016      | 0.0137 ± 0.0096        | 5.0718  |
| 28       | Proteasome subunit beta type-1 | SwissProt| P18421[PSB1]| 26462.3/6.9         | 73         | 0.0132 ± 0.0022      | 0.0477 ± 0.00154       | 3.602   |

^aProtein spot numbers on 2DE gel.
^bAccession numbers from NCBI database (accessible at http://www.ncbi.nlm.nih.gov/) or the Swiss-Prot Protein Database (http://web.expasy.org/docs/swiss-prot_guideline.html).
^cTheoretical molecular mass.
^dTheoretical PI.
^eMASCOT protein score (based on combined MS and MS/MS spectra) of greater than 64 (P<0.05) or the total ion score (based on MS/MS spectra) of greater than 30 (P<0.05).

doi:10.1371/journal.pone.0067942.t002
Table 3. Up-regulated proteins identified by MS or MS/MS and database searches in the normoxia group.

| Spot no. | Protein description | Database accession | Database | Theoretical MW (Da) | PI Score Move | Intensity Mean ± SEM | Ratio Normoxia/Hypoxia | Protein description | P Value |
|----------|---------------------|--------------------|----------|--------------------|---------------|---------------------|----------------------|---------------------|----------|
| 5        | Cytochrome-b5        | SwissProt sp|P00173| CYB5 | 15345.6/4.9 | 0.0472 | 0.0161 | 2.133 | 0.002 |
| 6        | Polymerase I and transcript release factor | SwissProt sp|P85125| PTRF | 43882/5.34 | 0.0196 | 0.0019 | 2.122 | 0.004 |
| 10       | NADH dehydrogenase 1 alpha subcomplex subunit 10 | SwissProt sp|P52928| NDUA | 40467.6/7.64 | 0.0199 | 0.0020 | 2.472 | 0.008 |
| 11       | Adiponectin          | NCBInr gi|21426809| ST1A1 | 26392.9/5.42 | 0.0187 | 0.0051 | 2.938 | 0.001 |
| 19       | Sulfotransferase 1A1 | SwissProt sp|P17988| ST1A1 | 33884/6.37 | 0.0137 | 0.0031 | 3.0065 | 0.0257 |

Protein Isolation and Western Blotting

Pulmonary artery tissue was homogenized by sonication and dissolved in lysis buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% protease inhibitor cocktail, 1 mM EDTA, and 200 μM 4-[(2-aminoethyl)benzenesulfonyl fluoride hydrochloride. Total protein concentration in the homogenates was determined using the BCA Protein Assay Kit (Bio-Rad, USA) with bovine serum albumin as a standard (Calbiochem, San Diego, CA). The extracted protein samples were stored at −80°C. Homogenates were denatured by adding dithiothreitol to 150 mM and heating at 95°C for 3 min. The homogenized proteins were resolved by 12% SDS-PAGE calibrated with prestained protein molecular weight markers (Precision Plus, Bio-Rad, Carlsbad, CA). Separated proteins were transferred to polyvinylidene difluoride membranes (pore size 0.45 μm, BioRad), and the membranes were blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.2% Tween 20 and blotted with affinity-purified polyclonal antibodies specific for PSMB6 (G-16, Santa Cruz Biotechnology, USA), PSMB1 (11749-1-AP,ProteinTech, USA), or a monoclonal antibody against α-actin (Sigma, USA). The membranes were then washed 5 times for 5 min each with a 1×Tris-buffered saline (TBS) solution with Tween-20 and incubated with horseradish peroxidase-conjugated rabbit anti-goat, goat anti-rabbit, or goat anti-mouse IgG for 1 h. Bound antibodies were detected using an enhanced chemiluminescence system (ECL, GE Healthcare, Piscataway, NJ).

Proteosome Function Assays

Chymotryptic proteasome activities of PA and PASMCs were measured as previously described with a few minor modifications [23]. Briefly, PASMCs and PA were sonicated in homogenization buffer (25 mM Tris [pH 7.5], 100 mM NaCl, 5 mM ATP, 0.2% (v/v) Nonidet P-40, and 20% glycerol), and cell debris were removed by centrifugation at 4°C. Protein concentration in the resulting crude cellular extracts was determined using the BCA Protein Assay Kit. To measure 26S proteasome activity, 50 μg of protein from the crude cellular extracts of each sample was diluted with buffer I (50 mM Tris [pH 7.4], 2 mM dithiothreitol, 5 mM MgCl2, and 2 mM ATP) to a final volume of 200 μl (assayed in quadruplicate). The fluorogenic proteasome substrate, Suc-LLVY-AMC (chymotryptic substrate; Calbiochem), was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 80 mM. Proteolytic activities were continuously monitored for 2 h at 37°C by measuring the release of the fluorescent group, 7-amido-4-methylcoumarin (AMC), with a fluorescence plate reader (Vario Skanlux); the excitation and emission wavelengths were 380 and 460 nm, respectively.

GAG: R: TAAAACAAACGTGCCACAGC; 18S (F: GCCAT-TAT1CCCATGAACGC; R: ACCTGCTAAACACCCT-CAA). The real-time qPCR program consisted of three steps, including a hot start at 95°C for 15 min, 40 cycles at 94°C for 15 s, 57.5°C for 20 s, and 72°C for 20 s, and melting curves were performed at 95°C for 1 min and 55°C for 1 min, with 80 repeats of incremental increases of 0.5°C. Detection of the cycle threshold (CT) values was performed with iCyclerIQ software. Specificity of the PCR products was confirmed by the melting curve and DNA sequencing. Standard curves were analyzed for all genes to assess the efficiency of amplification of each gene. The relative concentration of each transcript was calculated using the Pfaffl method [22]. Data were expressed as a ratio of PSMB6 and PSMB1 to 18S in the same sample.
MTT Cell Proliferation Assay

PASMC proliferation was measured using an MTT assay (Sigma, USA). In short, PASMCs were seeded at a density of 5000 cells/cm² in 96-well plates. The cells were incubated for 24 h in serum-free SMBM, and were then exposed to MG132 (0, 0.01, 0.05, 0.1, and 0.2 µM) for 60 h in normoxia or hypoxia (4% O₂). Plain SMBM was used as the negative control. At the end of treatment, MTT at 0.25 mg/mL was added to the plates, and incubation continued for another 4 h at 37°C. The supernatant was then carefully removed, and 150 µl of DMSO was added to dissolve the formazan crystals. The absorbance of the solubilized product at 490 nm (A490) was measured with an ELISA reader (Thermo Scientific Varioskan Flash, USA). All determinations were confirmed in at least three identical experiments.

PSMB6 Small Interfering RNA Transfection (siRNA)

The siRNA specific for PSMB6 (siPSMB6) was designed according to Genebank accession number NM_057099.3 for PSMB6 mRNA and was purchased as ON-TARGETplus SMARTpool from Thermo Fisher Scientific Inc. (Lafayette, CO). The detailed siRNA treatment protocol was performed per the manufacturer’s instructions. The effect of siPSMB6 was verified by Western blot. PASMCs at about 50–60% confluence were transfected with 25 nM of non-targeting control siRNA (siNT) or siPSMB6 (using GeneSilencer [GeneSilencer, San Diego, CA]) for 6 h in serum-free SMBM. Serum was then added to a final concentration of 0.3% FBS. PASMCs were exposed to siRNA for 72 h before subsequent analysis with Western blot.

5’-bromo-2’-deoxyuridine (BrdU) Cell Proliferation Assay

The proliferation of PASMCs incubated with siPSMB6 was assessed using the Amersham Cell Proliferation Biotrak ELISA kit (GEhealthcare, Buckinghamshire, UK). Cells were plated into 96-well plates at 3 ×10³ cells/well and cultured for 24 h in SMGM-2 basal medium. Then, the cells were transfected with 25 nM siRNA for 6 h in serum-free SMBM using GeneSilencer (GeneSilencer, San Diego, CA) according to the manufacturer’s instructions. After a further 36 h culture in SMBM containing 0.3% FBS, the cells were subjected to normoxic or hypoxic (4% O₂, 60 h) exposure. The BrdU reagent was diluted (1:100) and incorporated into the proliferating cells 24 h prior to subsequent ELISA assay for BrdU incorporation according to the manufacturer’s instructions. The amount of BrdU incorporated into the cells was measured as optical density (OD) using a spectrophotometer microplate reader (Benchmark microplate reader, BioRad, USA) at a wavelength of 450 nm.

Figure 2. Verification of PSMB6 expression in the PA under prolonged hypoxia. A: Zoomed-in view of protein spot 14 in the 2DE gel in Fig. 1. B: Relative protein expression of PSMB6 in the 2DE gel. The normoxia group was considered as 100% and the relative fold-change in protein level is shown by spot density. C: Relative mRNA levels for PSMB6 from the PA of rats exposed to 10% O₂ for 21 days compared with the normoxia control. Bar values are mean ± SEM (n = 5 in each group). *P < 0.05 versus respective normoxia control. D: Protein levels of PSMB6 measured by Western blot in the PA isolated from rats exposed to hypoxia (10% O₂, 21 days) or normoxia. E: Band intensity of PSMB6 normalized to α-actin. Mean values ± SEM were calculated from three independent samples. *P < 0.01 versus normoxia.
doi:10.1371/journal.pone.0067942.g002
**Figure 3. Verification of PSMB1 expression in PA under prolonged hypoxia.**

A: Zoomed-in view of protein spot 28 in the 2DE gel in Fig. 1.

B: Relative protein expression of PSMB1 in the 2DE gel. The normoxia group was considered as 100% and the relative fold-change in protein level is shown by spot density.

C: Relative mRNA levels for PSMB1 from the PA of rats exposed to 10% O2 for 21 days compared with normoxia control. Bar values are mean ± SEM (n = 5 in each group). *P<0.05 versus respective normoxia control.

D: Protein levels of PSMB1 measured by Western blot in PA isolated from rats exposed to hypoxia (10% O2, 21 days) or normoxia. E: Band intensity of PSMB1 normalized to α–actin. Mean values ± SE were calculated from three independent samples. *P<0.01 versus normoxia.

doi:10.1371/journal.pone.0067942.g003

**Figure 4. Proteasome activity of PASMCs and PA exposed to hypoxia.**

A: Activity of 20S proteasome in PASMCs incubated with normoxia or hypoxia (4% O2, 60 h). The activity in the control group was considered as 100%. Proteasome activities in PASMCs exposed to hypoxia were enhanced compared with the normal controls (n = 4, *P<0.05).

B: Activity of 20S proteasome in PA isolated from normoxic or hypoxic (10% O2, 21 days) rats. The activity in the normoxic control group was considered as 100% and the proteasome activity in hypoxic group was approximately 1.7-fold of the normal control (n = 3, *P<0.05).

doi:10.1371/journal.pone.0067942.g004
Statistical Analysis
Parameters are expressed as mean ± standard deviation. For the 2DE experiment, ‘n’ represents the number of samples; this is because we combined the PA from 2 rats as 1 sample. For the other experiments, ‘n’ is the number of experiments performed, which equals the number of animals providing PA or cells. Statistical comparisons were performed using a Student’s T-test or ANOVA as appropriate. Differences were considered to be significant when \( P < 0.05 \).

Results
Verification of CHPH Model in Rats
Twenty male SD rats were randomly divided into two groups: normoxic group (10 rats) and CH group (10 rats). After the rats were placed in the CH chamber (10% O2) for 21 days, the CHPH model was successfully established as measured by the indexes of right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (mPAP), and the weight ratio of right ventricle to left ventricle plus septum RV/(LV+S). Compared with the normoxic group, RVSP and mPAP were significantly increased in the CH group. Right ventricular hypertrophy also occurred in the CH group as indicated by the increased weight ratio of RV/(LV+S) (Table 1). These results are consistent with our previous report [24].

Two-dimensional Electrophoresis Analysis of the Protein Expression in Distal PA Isolated from Rats Exposed to Normoxia and CH
Protein samples of rat distal PA were pooled from both normoxic and CH groups and subjected to 2DE separation. Hundreds of highly-resolved protein spots were visible when the 2DE gels were silver-stained. The results of the quantitative comparison revealed that 29 protein spots were significantly differentially expressed between the CH group and the control group. The representative gels of the two groups are shown in Figure 1.

MALDI-TOF MS Identified Differentially Expressed Proteins and Bioinformatics
The proteins with differential expression of at least 2-fold between the normoxic and CH group were considered to be differentially expressed. According to this criterion, the 29 spots marked in Figure 1 were selected for identification. In total, 22 out of the 29 spots were excised from the gels and identified with confidence by peptide mass fingerprinting and tandem mass spectrometry. The results showed that 17 proteins were up-regulated in the CH group while 5 proteins were up-regulated in the normoxic group. The detailed corresponding information of those differentially expressed proteins is listed in Table 2 and Table 3, among which PSMB1 and PSMB6 were identified as subunits of the proteasome within the UPS. Our study mainly focused on the differentially expressed key components of the UPS, and therefore, PSMB6 was further analyzed.

Real-time PCR Analysis of the mRNA Expression of PSMB6 and PSMB1
In an attempt to confirm the proteomic results, alterations in the mRNA level of PSMB6 in the distal PA in CH group and the control group were analyzed using real-time PCR. As shown in Figure 2C and Figure 3C, PSMB6 and PSMB1 mRNA levels were up-regulated in the isolated distal PA from CH rats as compared with the normoxia controls.

Western Blotting Confirmed the Up-regulation of PSMB6 and PSMB1
The increased expression of PSMB6 and PSMB1 was validated through Western blotting. Figure 2 shows the comparison of PSMB6 and α-actin in the distal PA isolated from the control group and the CH group. Figure 3 shows the results of the
comparison between PSMB1 and \( \alpha \)-actin. Results indicated that the expression of PSMB6 and PSMB1 in the CH group was significantly higher than that of the normoxic control group \((P, 0.01)\). These data were in accordance with the results obtained through the 2DE.

**Identification of Proteasome Activities in PASMCs and PA Isolated from Rats Exposed to both Normoxia and Hypoxia**

We analyzed the proteasome activity in hypoxia-exposed PASMCs \( \text{ex vivo} \) and in the distal PA from CHPH rats \( \text{in vivo} \). The chymotrypsin-like activity of PASMCs and PA from normoxic and hypoxic conditions was measured. Endpoint analysis (120 min) of the 20S proteasome activity from the hypoxic group is shown as percent to normoxic control, while the activity of the 20S proteasome in the control was considered to be 100%. Results demonstrated that the proteasome activity in hypoxia-exposed PASMCs was significantly enhanced compared with the normoxic controls (Figure 4). In the distal PA from rats exposed to CH for 21 days, the proteasome activity was observed to be approximately 70% higher than the normoxic control.

**Analysis of PASMC Proliferation by MTT Assay**

To investigate the role of the proteasome in vascular remodeling during rat CHPH development, an MTT assay was performed. PASMCs were seeded in a 96-well plate at a density of \( 5 \times 10^3 \) cells per well and were exposed to various concentrations of MG132, a proteasome inhibitor, for 60 h under either normoxic or hypoxic conditions. Results revealed that hypoxia could induce the proliferation of PASMCs, while MG132 treatment remarkably attenuated such hypoxic induction in a dose-dependent manner (Figure 5).

**Knockdown of PSMB6 Prevented Hypoxia-induced Proliferation**

The effects of PSMB6 inhibition by siRNA on proliferation were also evaluated. Indeed, by using siPSMB6 at a dose of 25 nM, an approximate 60% decrease in the expression of PSMB6 proteins was observed (Figures 6A and B). To estimate the functional influences of PSMB6, we further investigated the effects of siPSMB6 on PASMC proliferation. As shown in Figure 6C, exposure to prolonged hypoxia (4% O\(_2\), 60 h) lead to a 51% increase in PASMC proliferation; treatment with siPSMB6 inhibited these increases.

**Discussion**

In this study, we employed a classical proteomic strategy, 2DE for protein separation and mass spectrometry, to investigate differentially expressed proteins in the distal PA isolated from rats exposed to CH and normoxia. An important component of the UPS, PSMB6, was initially detected to be significantly up-regulated in the distal PA from CH rats. This up-regulation was further confirmed by real-time PCR and Western blotting. Additionally, proteasome activity was also enhanced by hypoxia in both PA and cultured PASMCs. Both of the proteasome
Proteomic Reveals that PSMB6 Is Involved in CHPH

These findings were largely consistent with earlier studies in other animal models, indicating the role of proteasome activity in cardiovascular disease and demonstrating that the use of a proteasome inhibitor could rescue vascular or heart remodeling and suppress further progression of hypertrophy or proliferation [10,34–36]. All these findings suggest that increased PSMB6 expression was involved in the pathogenesis of rat CHPH.

The finding that proteasome is involved in pathogenesis of PH may provide a new strategy for its treatment. Kim et al. found that a proteasome inhibitorameliorated PA in chronic hypoxia- and monocrotaline-induced PH animal models [37]. Some transcriptional factors associated with hypoxia diseases, like COPD and pulmonary hypertension, are also related to the proteasome. The Nrf2 activator olitipraz, which was demonstrated to attenuate CHPH in mice [38], can regulate PSMB6 expression [39]. TCF11, which plays an important role in COPD, is a key regulator for UPS [40] and 26S PSMB6 [41].

In our experiments, increased PSMB6 expression and proteasome activity in a hypoxia-induced animal model are significantly more pronounced in PA than those in cultured PASMCs exposed to hypoxia. This may indicate that other cell types are involved. Since adventitia and connective tissue were carefully removed, endothelial cells may be required for the observed effects. Kim et al. found that bortezomib, a proteasome inhibitor, could increase eNOS and NO expression in PA endothelial cells both in vivo and in vitro [37]. It was also reported that MG132 could inhibit the growth of calf pulmonary arterial endothelial cells and also induce apoptosis [42]. It is plausible that PSMB6 may also play a role in endothelial cells; however, further study is required to elucidate the mechanism(s).

2DE, in combination with MS, plays a central role in proteomics; however, several limitations and issues have been recognized [43]. The most important drawback of 2DE-based proteomics is that it is not possible to analyze the entire proteome. Low-abundant proteins, which include regulatory proteins, receptors, and other proteins that play key roles in cellular processes, are not detected by conventional staining. Silver staining detects the quantity of protein in a silver-stained spot is generally low [44]. This may be the reason why prominent markers of hypoxia, such as HIF-1, were not observed.

In summary, the present study revealed for the first time that one of the proteasome subunits, PSMB6, was increased in the distal PA from a CHPH rat model. The proteasome activity and the proliferation of PASMCs were also found to be up-regulated. However, both the proteasome inhibitor MG132 and siPSMB6 could prevent hypoxia-induced proliferation in PASMCs. These results suggest an association between increased PSMB6 and the development of CHPH, as well as the likely essential role of PSMB6 during the CHPH process. However, the detailed mechanism remains largely unclear and requires further exploration.

Author Contributions
Conceived and designed the experiments: JW WL. Performed the experiments: LX DL XY. Analyzed the data: JW WL LX. Contributed reagents/materials/analysis tools: KY LT HJ. Wrote the paper: JW WL LX.

References
1. Tashkin DP, Murray RP (2009) Smoking cessation in chronic obstructive pulmonary disease. Respir Med 103: 963–974.

2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelemeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive...
18. Shimoda LA, Wang J, Sylvester JT (2006) Ca2+
17. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal
16. Weiss CH, Budinger GR, Mutlu GM, Jain M (2010) Proteasomal regulation of
15. Han YH, Park WH (2010) MG132 as a proteasome inhibitor induces cell growth
14. Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, et al. (2013) The Nrf2
13. Ma Y, Chen B, Liu D, Yang Y, Xiong Z, et al. (2011) MG132 treatment
12. Powell SR, Herrmann J, Lerman A, Patterson C, Wang X (2012) The ubiquitin-
11. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, et al. (2008) Proteasome
10. Hedhli N, Depre C (2010) Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 85: 321–329.
9. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, et al. (2008) Proteasome
8. Li HH, Du J, Fan YN, Zhang ML, Lu DP, et al. (2011) The ubiquitin ligase
7. Huang H, Liu N, Yang C, Liao S, Guo H, et al. (2012) HDAC inhibitor L-carntine and protease inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One 7: e32576.
6. Chauhan D, Bianchi G, Anderson KC (2008) Targeting the UPS as therapy in multiple myeloma. BMC Biochem 9 Suppl 1: S1.
5. D’Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, et al. (2011) Proteasome
4. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric
3. Beranova-Giorgianni S (2003) Proteome analysis by two-dimensional gel (2-DE) electrophoresis and mass spectrometry. Results Probl Cell Differ 22: 133–160.
2. Zwickl P, Voges D, Baumeister W (1999) The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354: 1501–1511.
1. Tanaka K (1998) Proteasomes: structure and biology. J Biochem 123: 195–204.
0. Lupas A, Koster AJ, Baumeister W (1993) Structural features of 26S and 20S proteasomes. Enzyme Protein 47: 232–273.
-1. Sardi Y, Tanaka K (2012) Assembly and function of the proteasome. Methods Mol Biol 832: 315–337.
-2. Wang C, Wang J, Zhao L, Wang Y, Liu J, et al. (2008) Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing caspase-3 and caspase-9 expression. J Pharmacol Sci 106: 71–78.
-3. Luo Y, Xu DQ, Dong HY, Zhang B, Liu Y, et al. (2013) Tanshinone IIA inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt/Skp2/p27-associated pathway. PLoS One 8: e56774.
-4. Deppe C, Wang Q, Yan L, Hedhli N, Peter P, et al. (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821–1828.
-5. Bulbele AL, Landberg KC, Humphries KM, Sadek HA, Sreedhar PA, et al. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057–30063.
-6. Divald A, Kivity S, Wang P, Hochhauser E, Roberts B, et al. (2010) Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 106: 1829–1838.
-7. Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, et al. (2012) Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol 48: 698–708.
-8. Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Sato H, et al. (2013) The Nrf2 Activator Oltipraz Attenuates Chronic Hypoxia-Induced Cardiopulmonary Alterations In Mice. Am J Respir Cell Mol Biol.
-9. Malhotra D, Thimmulappa R, Vj N, Navas-Acien A, Susan T, et al. (2009) Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 180: 1196–1207.
-10. Koch A, Steffen J, Kruger E (2011) TCF11 as a crossroad of oxidative stress and the ubiquitin proteasome system. Cell Cycle 10: 1200–1207.
-11. Steffen J, Seeger M, Koch A, Kruger E (2010) Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell 40: 147–158.
-12. You BR, Park WH (2011) MG132, a proteasome inhibitor-induced calf pulmonary arterial endothelial cell growth and death, are changed by MAPK pathway. Am J Respir Cell Mol Biol 48: 347–365.
-13. Beranová-Giorgianni S (2003) Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitations. Trends in Analytical Chemistry. 273–281.
-14. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 68: 850–856.